Frankfurt
06.06.25 | 15:29
2,860 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.05. | INVENTIVA: Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference | 266 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), May 27, 2025 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 23.05. | Inventiva S.A. reports Q1 results | 1 | Seeking Alpha | ||
| 23.05. | INVENTIVA: Inventiva reports 2025 First Quarter Financial Information | 312 | GlobeNewswire (Europe) | Cash and cash equivalents at €67.9 million
Daix (France), New York City (New York, United States), May 23, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| INVENTIVA SA ADR Aktie jetzt für 0€ handeln | |||||
| 23.05. | INVENTIVA: Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025 | 149 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), May 23, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 22.05. | Inventiva S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 22.05. | Inventiva sets share repurchase program terms post-meeting | 5 | Investing.com | ||
| 22.05. | INVENTIVA: Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux | 233 | GlobeNewswire (Europe) | Daix, May 22, 2025
Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l'Autorité des marchés financiers), the purpose of this description is to present the objectives... ► Artikel lesen | |
| 05.05. | Inventiva secures €116 million second tranche of structured financing of up to €348 million | 2 | Seeking Alpha | ||
| 05.05. | INVENTIVA: Inventiva secures the €116 million second tranche of its structured financing of up to €348 million | 317 | GlobeNewswire (Europe) | Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions.
Daix (France), New York City (New York, United... ► Artikel lesen | |
| 02.05. | Inventiva S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 30.04. | INVENTIVA: Combined General Meeting of May 22, 2025 - Availability of the preparatory documents | 246 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), April 30, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small... ► Artikel lesen | |
| 30.04. | INVENTIVA: Statement of total voting rights and shares forming the company's share capital as of April 11, 2025 | 235 | GlobeNewswire (Europe) | Article R. 22-10-23 of the French Commercial Code
Market: Euronext ParisISIN code / Mnemo: FR0013233012 / IVAWeb site: www.inventivapharma.com
DateNumber of shares outstandingTotal voting rights... ► Artikel lesen | |
| 24.04. | INVENTIVA: Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor | 312 | GlobeNewswire (Europe) | ? Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis
? The biomarker signatures developed for fibrosis improvement... ► Artikel lesen | |
| 24.04. | Inventiva S.A. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 15.04. | INVENTIVA: Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F | 651 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), April 15, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 15.04. | Inventiva S.A. - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 11.04. | Inventiva S.A. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 04.04. | Guggenheim cuts Inventiva stock target to $9, maintains Buy rating | 1 | Investing.com | ||
| 02.04. | Inventiva stock rises following NATiV3 trial enrollment completion | 3 | Investing.com | ||
| 02.04. | Inventiva-Aktie steigt nach Abschluss der NATiV3-Studienrekrutierung | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 5,030 | +0,20 % | Aurora Cannabis Inc (3): Aurora Cannabis launches IndiMed Tempo 22 | ||
| CANOPY GROWTH | 1,498 | +0,67 % | Canopy Growth has price target chopped at Roth | ||
| TILRAY BRANDS | 0,357 | +0,11 % | Tilray Brands Inc: Tilray Brands to be deleted from S&P/TSX Composite | ||
| TEVA | 15,250 | -2,24 % | Teva Pharmaceutical: Teva 2024 Healthy Future Report: Health System Strengthening and Capacity Building | NORTHAMPTON, MA / ACCESS Newswire / June 6, 2025 / Teva Pharmaceutical:At Teva, we are all in for better health. Increasing access to quality medicines is fundamental to improving the health of patients... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 395,50 | +0,08 % | Vertex Pharmaceuticals Incorporated: Vertex Presents New Data on Benefits of ALYFTREK and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference | - Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with... ► Artikel lesen | |
| ARZNEIWERK AG VIDA | 0,695 | +10,32 % | PTA-AFR: Arzneiwerk AG VIDA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Arzneiwerk AG VIDA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Arzneiwerk... ► Artikel lesen | |
| CRONOS GROUP | 1,728 | -0,80 % | Cronos Group Inc.: Cronos Group Reports 2025 First Quarter Results | Net revenue in Q1 2025 increased by 28% year-over-year, 33% year-over-year net revenue growth on a constant currency basis PEACE NATURALS® retained its position as the number one cannabis brand in... ► Artikel lesen | |
| VIATRIS | 7,584 | -0,73 % | Viatris Reports Positive Top-line Results From LYNX-2 Phase 3 Trial With MR-142 | WASHINGTON (dpa-AFX) - Viatris (VTRS) reported positive top-line results from LYNX-2, a Phase 3 trial evaluating MR-142 in treating significant, chronic night driving impairment in keratorefractive... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 7,718 | -1,56 % | EyePoint Pharmaceuticals, Inc.: EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration | - Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest - - LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of... ► Artikel lesen | |
| INCYTE | 58,90 | -2,42 % | Incyte kündigt mehrere Präsentationen an, darunter neue aktuelle Daten zu seinem mutCALR-gerichteten monoklonalen Antikörper (INCA033989), die zur Präsentation auf der EHA 2025 angenommen wurden | In einer Late-Breaking mündlichen Präsentation werden neue Daten aus einer Studie mit INCA033989 vorgestellt, einem gegen mutiertes Calreticulin (mutCALR) gerichteten monoklonalen Antikörper... ► Artikel lesen | |
| BAUSCH HEALTH | 4,220 | +1,15 % | Bausch Health Companies Inc: Bausch Health Announces 2025 Annual Meeting of Shareholder Results | LAVAL, QC / ACCESS Newswire / May 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the election of the 10 directors nominated at its 2025 annual meeting of shareholders ("Annual... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 67,46 | -0,82 % | Is Edwards Lifesciences Stock Underperforming the Dow? | ||
| IONIS PHARMACEUTICALS | 30,650 | +0,46 % | Ionis Pharmaceuticals, Inc.: Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. | - Agreement enables olezarsen to reach people living with conditions associated with elevated triglycerides across the world - - Ionis will continue to independently commercialize TRYNGOLZA (olezarsen)... ► Artikel lesen | |
| CRESCO LABS | 0,496 | +1,85 % | Canaccord Genuity stuft Cresco Labs-Aktie aufgrund von Wettbewerbsdruck herab | ||
| BAYER | 26,435 | +0,02 % | Bayer, Deutsche Bank, Volkswagen und Co: Unterbewertete deutsche Aktien mit Comeback-Potenzial | Die Rheinmetall-Aktie ist in diesem Jahr bereits um 200 Prozent gestiegen. Doch nicht jede deutsche Aktie kann eine solche Performance aufweisen. Wie es bei Bayer, Deutsche Bank, Volkswagen und Co steht... ► Artikel lesen |
Das Unternehmen INVENTIVA SA ADR kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,860 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INVENTIVA SA ADR finden Sie auf Wallstreet Online.